Literature DB >> 23921754

Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies.

Andrew S Lee1,2,3, Chad Tang1,4, Mahendra S Rao5, Irving L Weissman1, Joseph C Wu1,2,3.   

Abstract

Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the Kobe Center for Developmental Biology for the treatment of spinal cord injury and macular degeneration. Despite their therapeutic promise, a crucial hurdle for the clinical implementation of human PSCs is their potential to form tumors in vivo. In this Perspective, we present an overview of the mechanisms underlying the tumorigenic risk of human PSC-based therapies and discuss current advances in addressing these challenges.

Entities:  

Mesh：

Year:  2013        PMID： 23921754      PMCID： PMC3967018          DOI： 10.1038/nm.3267

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  63 in total

1.  Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells.

Authors:  Jonathan S Draper; Kath Smith; Paul Gokhale; Harry D Moore; Edna Maltby; Julie Johnson; Lorraine Meisner; Thomas P Zwaka; James A Thomson; Peter W Andrews
Journal:  Nat Biotechnol       Date:  2003-12-07       Impact factor: 54.908

2.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

Authors:  Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Lancet       Date:  2004 Jul 10-16       Impact factor: 79.321

3.  Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues.

Authors:  Konrad Hochedlinger; Yasuhiro Yamada; Caroline Beard; Rudolf Jaenisch
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

4.  CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells.

Authors:  Daniella Herszfeld; Ernst Wolvetang; Emma Langton-Bunker; Tung-Liang Chung; Adam A Filipczyk; Souheir Houssami; Pegah Jamshidi; Karen Koh; Andrew L Laslett; Anna Michalska; Linh Nguyen; Benjamin E Reubinoff; Irene Tellis; Jonathan M Auerbach; Carol J Ording; Leendert H J Looijenga; Martin F Pera
Journal:  Nat Biotechnol       Date:  2006-02-26       Impact factor: 54.908

5.  Copy number variation and selection during reprogramming to pluripotency.

Authors:  Samer M Hussein; Nizar N Batada; Sanna Vuoristo; Reagan W Ching; Reija Autio; Elisa Närvä; Siemon Ng; Michel Sourour; Riikka Hämäläinen; Cia Olsson; Karolina Lundin; Milla Mikkola; Ras Trokovic; Michael Peitz; Oliver Brüstle; David P Bazett-Jones; Kari Alitalo; Riitta Lahesmaa; Andras Nagy; Timo Otonkoski
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

6.  Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes.

Authors:  Neeta S Roy; Carine Cleren; Shashi K Singh; Lichuan Yang; M Flint Beal; Steven A Goldman
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

7.  Induction of tumors in mice by genomic hypomethylation.

Authors:  François Gaudet; J Graeme Hodgson; Amir Eden; Laurie Jackson-Grusby; Jessica Dausman; Joe W Gray; Heinrich Leonhardt; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

8.  The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

Authors:  Benjamin D Rowland; René Bernards; Daniel S Peeper
Journal:  Nat Cell Biol       Date:  2005-11       Impact factor: 28.824

9.  Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.

Authors:  William M Rideout; Konrad Hochedlinger; Michael Kyba; George Q Daley; Rudolf Jaenisch
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

10.  Combined management of malignant teratoma of the testis.

Authors:  M J Peckham; T J McElwain; A Barrett; W F Hendry
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321
View more
  247 in total

1.  Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons.

Authors:  Lei Zhang; Jiu-Chao Yin; Hana Yeh; Ning-Xin Ma; Grace Lee; Xiangyun Amy Chen; Yanming Wang; Li Lin; Li Chen; Peng Jin; Gang-Yi Wu; Gong Chen
Journal:  Cell Stem Cell       Date:  2015-10-17       Impact factor: 24.633

2.  Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.

Authors:  Erin M Kropp; Bryndon J Oleson; Katarzyna A Broniowska; Subarna Bhattacharya; Alexandra C Chadwick; Anne R Diers; Qinghui Hu; Daisy Sahoo; Neil Hogg; Kenneth R Boheler; John A Corbett; Rebekah L Gundry
Journal:  Stem Cells Transl Med       Date:  2015-04-01       Impact factor: 6.940

Review 3.  The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Authors:  Zachary S Scheiner; Sohel Talib; Ellen G Feigal
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

4.  Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma.

Authors:  Mitra Khalili; Mohammad Vasei; Davood Khalili; Kamran Alimoghaddam; Majid Sadeghizadeh; Seyed Javad Mowla
Journal:  J Gastrointest Cancer       Date:  2015-09

5.  Teratoma formation: a tool for monitoring pluripotency in stem cell research.

Authors:  Raman V Nelakanti; Nigel G Kooreman; Joseph C Wu
Journal:  Curr Protoc Stem Cell Biol       Date:  2015-02-02

6.  Cardiac Cell Cycle Activation as a Strategy to Improve iPSC-Derived Cardiomyocyte Therapy.

Authors:  June-Wha Rhee; Joseph C Wu
Journal:  Circ Res       Date:  2018-01-05       Impact factor: 17.367

7.  Stem cell therapy: a look at current research, regulations, and remaining hurdles.

Authors:  Miriam Reisman; Katherine T Adams
Journal:  P T       Date:  2014-12

8.  Preclinical Liver Bud Engineering towards Clinical Target for Liver Diseases.

Authors:  Shibashish Giri; Augustinus Bader
Journal:  J Clin Exp Hepatol       Date:  2014-04-18

Review 9.  Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.

Authors:  Patricia K Nguyen; Evgenios Neofytou; June-Wha Rhee; Joseph C Wu
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

Review 10.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.